Format

Send to

Choose Destination
See comment in PubMed Commons below
Am J Kidney Dis. 2008 Sep;52(3):475-85. doi: 10.1053/j.ajkd.2008.03.008. Epub 2008 May 12.

Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression.

Author information

1
Nephrology Division at Second University of Naples-S.M.d.P. Incurabili Hospital-ASL Na1, Naples, Italy.

Abstract

BACKGROUND:

In patients with primary glomerulonephritis (GN), antiproteinuric response to angiotensin-converting enzyme (ACE) inhibitors plus angiotensin receptor blockers (ARBs) versus either monotherapy is undefined because of the small size of studies and high heterogeneity of response.

STUDY DESIGN:

Meta-analysis/metaregression.

SETTING & POPULATION:

Randomized clinical trials (RCTs).

SELECTION CRITERIA FOR STUDIES:

RCTs published from January 1996 to April 2007. Studies were excluded if information about levels of proteinuria was not available, patients had kidney disease other than primary GN, or if they had end-stage renal disease.

INTERVENTION:

ACE inhibitor plus ARB versus monotherapy with 1 of these drug classes.

OUTCOMES:

Absolute changes in proteinuria (primary), blood pressure, serum potassium level, and glomerular filtration rate (GFR; secondary).

RESULTS:

We found 13 RCTs including 425 patients with primary GN with proteinuria ranging from 0.8 to 7.9 g/d of protein and age from 25 to 60 years. Combination treatment decreased proteinuria by 0.60 g/d (95% confidence interval, 0.40 to 0.80) versus ACE-inhibitor monotherapy and 0.54 g/d (95% confidence interval, 0.30 to 0.78) versus ARB monotherapy. Baseline levels of proteinuria explained most between-study variability of the antiproteinuric response to combination therapy versus monotherapies. Systolic and diastolic blood pressure, GFR, age, and diagnosis of immunoglobulin A nephropathy did not modify antiproteinuric response. ACE-inhibitor plus ARB therapy did not change GFR, whereas it increased serum potassium levels (by 0.10 mEq/L versus ACE-inhibitor and 0.19 mEq/L versus ARB therapy) and decreased blood pressure.

LIMITATIONS:

Only published data are included.

CONCLUSIONS:

The antiproteinuric response to ACE-inhibitor plus ARB therapy versus either monotherapy is consistently greater and strictly related to baseline proteinuria, associated with only moderate increase in serum potassium levels, and not peculiar to immunoglobulin A nephropathy.

PMID:
18468748
DOI:
10.1053/j.ajkd.2008.03.008
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Health
    Loading ...
    Support Center